Document:

EXHIBIT 10.5

                                LETTER OF INTENT

                          RELATING TO THE FORMATION OF

                          EUROMAGNEGAS AND ASIAMAGNEGAS

         This Letter of Intent is a part of that certain Worldwide Exclusive
Assignment, License and Royalty Agreement by and between Hadronic Press, Inc.,
and EarthFirst Technology, Inc. of equal date herewith to which Agreement this
Letter of Intent is annexed as Exhibit _)

         THIS LETTER OF INTENT is entered into by and between Hadronic Press,
Inc., 35246 US 19 No., PBM 115, Largo, Florida 34684 ("HPI" and USMAGNEGAS, Inc
35246 US Highway 19, North, Suite 115, Palm Harbor, Fl 34684, ("USM") (the
"Letter")

         WHEREAS, jointly with this Letter, HPI has entered into that Worldwide
Exclusive Assignment, License and Royalty Agreement relating to the Technology
as that term is therein defined.

         WHEREAS, upon incorporation of either or both EuroMagneGas and
AsiaMagneGas, USMAGNEGAS shall automatically amend its exclusive rights under
the Worldwide Exclusive Assignment, License and Royalty Agreement such that HPI
shall enter separate license agreements with each EuroMagneGas and AsiaMagneGas.

         WHEREAS, the Parties hereon now desire to specify certain factors
relating to the formation of EuroMagneGas and AsiaMagneGas so as to provide for
the automatic formation, licensing and funding of each.

         NOW THEREFORE, intending to be legally bound, in addition to certain
portions of the Worldwide Exclusive Assignment, License and Royalty Agreement,
USM and HPI now further agree on the following terms and conditions:

         1.       Within three months following the execution of that Worldwide
Exclusive Assignment, License and Royalty Agreement, USM shall incorporate
EuroMagneGas in Manchester, England and AsiaMagneGas in Hong Kong, China, or
some other place as both parties may mutually agree.

         2.       Upon incorporation, EuroMagneGas and AsiaMagneGas shall enter
individual license agreements directly with HPI according to the terms and
conditions set forth in that certain Technology Exclusive License and Royalty
Agreement except as such is modified in the Worldwide Exclusive Assignment,
License and Royalty Agreement. There shall be no further action required on the
part of either EuroMagneGas, AsiaMagneGas nor the parties to the Worldwide
Exclusive

<PAGE>

Assignment, License and Royalty Agreement to cause for the execution and
delivery of the individual HPI-EuroMagneGas and HPI-AsiaMagneGas License
Agreements.

         3.       At the time of incorporation 80% of the stock of EuroMagneGas
and 80% of the stock of AsiaMagneGas will be issued to EarthFirst Technology,
Inc. ("EFT") and the remaining 20% in each said company will be issued to HPI.

         4.       Jointly with said Incorporation, USM will deliver to
EuroMagneGas and separately to AsiaMagneGas, copies of all construction drawings
on the Technology.

         5.       USM, EuroMagneGas and AsiaMagneGas shall thereafter enter into
an agreement of mutual collaboration, support and honor of their respective
areas of exclusivity.

         6.       USM shall pay the costs of incorporation of EuroMagneGas and
AsiaMagneGas, and their maintenance.

         7.       On or before six months from incorporation, corresponding to
nine months from the date of execution of the Worldwide Exclusive Assignment,
License and Royalty Agreement, EuroMagneGas and AsiaMagneGas shall receive
complete working prototypes of PlasmaArcFlow total recyclers and sewage
recyclers. USM shall bear all costs associated with this item 7.

         8.       On or before six months from their incorporation,
corresponding to nine months from the date of execution of Worldwide Exclusive
Assignment, License and Royalty Agreement, EuroMagneGas and AsiaMagneGas shall
formulate an operational plan for advertising marketing and sales promotions.

         9.       On or before six months from their incorporation,
corresponding to nine months from the date of this Agreement, EFT and HPI shall
reach agreement for the funding of EuroMagneGas and AsiaMagneGas so as to
support their operating plans for advertising, marketing and sales.

         10.      In the event of lack of funding by EFT, EFT and HPI agree to
capitalize EuroMagneGas and AsiaMagneGas via the sale of stock of these
companies to interested investors.

         11.      Upon incorporation through capitalization, Ruggero Santilli
shall be nominated as President of EuroMagneGas and AsiaMagneGas. Leon Toups
shall be the Executive Vice President and John Stanton shall be the Chairman of
the Board of Directors.

         12.      The initial Board of Directors of EuroMagneGas and
AsiaMagneGas shall be John Stanton and Leon Toups on behalf of USM and Ruggero
Santilli on behalf of HPI.

                                       2
<PAGE>

         13.      Upon the proper incorporation of EuroMagneGas, EFT shall issue
to HPI options to acquire 250,000 unregistered common EFT shares at the closing
"bid" price of EFT's common shares on the date of this Agreement or a ate of
$0.4375 per share (the closing "bid" price on July 5, 2000 of the EFT's publicly
traded securities) wherein such Options shall have an exercise period of three
years commencing on date of issuance.

         14.      Upon the proper incorporation of AsiaMagneGas, EFT shall issue
to HPI options to acquire 250,000 unregistered common EFT shares at the closing
"bid" price of EFT's common shares on the date of this Agreement or rate of
$0.4375 per share (the closing "bid" price on July 5, 2000 of the EFT's publicly
traded securities) wherein such Options shall have an exercise period of three
years commencing on date of issuance.

         IN WITNESS WHEREOF, the Parties have caused this instrument to be
properly executed on the date first given above.

For Hadronic Press, Inc.                    For USMAGNEGAS, Inc.

/s/ CARLA SANTILLI                          /s/ LEON TOUPS
------------------------                    -------------------------------
Carla Santilli, President                   Leon Toups, President

                                            Ratified by its Chairman of the
                                            Board of Directors

                                            /s/ JOHN STANTON
                                            -------------------------------
                                            John Stanton

                                       3EHXIBIT 10.6

                              CONSULTING AGREEMENT

         This Consulting Agreement is made this 7th day of July, 2000 by and
between Dr. Ruggero Maria Santilli 90 Eastwind Court, Palm Harbor, Florida
34683, the Institute for Basic Research, Inc. (collectively "Dr. Santilli" or
"Consultant") and USMAGNEGAS, Inc., 35246 US Highway 19 North, Suite 115, Palm
Harbor, Florida 34684 ("USM" or the "Company"). (The "Agreement")

         WHEREAS, Dr. Santilli and the Company are both parties to that certain
World-Wide Exclusive Assignment, License and Royalty Agreement and accompanying
Exhibits thereto including that certain Technology License and Royalty Agreement
(collectively the "Technology Agreement"), and;

         WHEREAS, the Parties hereto now desire to further define the
requirements of the Company and the obligations, responsibilities and
compensation for Dr. Santilli to supercede that described in the Technology
Agreement.

         NOW THEREFORE, the Parties hereon, intending to be legally bound, agree
to perform according to the terms and condition and for such compensation as is
herein set forth.

         1.       AGREEMENT TO ENGAGE AND BE ENGAGED. The Company hereby engages
Dr. Santilli as a Consultant and Dr. Santilli herein agrees to be engaged by the
Company as a Consultant, on behalf of Institute for Basic Research.

         2.       DUTIES AND RESPONSIBILITIES OF DR. SANTILLI.

                  a.       Dr. Santilli shall assume the role and title of the
Company's Director, Research and Development.

                  b.       Dr. Santilli shall at all times faithfully,
industriously and to the best of his ability, experience and talent, perform all
duties that may be required of and from him pursuant to the express and implicit
terms hereto, to the reasonable satisfaction of the Company.

                  c.       Dr. Santilli shall devote a minimum of 75%
(seventy-five percent) of a standard work week toward achieving the purpose of
this Agreement. A standard work week shall, for these purposes, be defined as
five consecutive eight hour days or a total of forty-hours per five day period
commencing on the Monday and concluding on the Friday of each week.

                  d.       Dr. Santilli's primary responsibilities shall be all
matters related to the research and development of the: Technology as that term
is defined in the Technology Agreement.

<PAGE>

                  c.       Subject to the supervision and pursuant to the
orders, advice and direction of the Company, Dr. Santilli shall perform such
duties as are customarily performed by one holding such position in other
businesses or enterprises of the same or similar nature as that engaged by the
Company. Dr. Santilli shall be available for presentations of the technology
anywhere in the world.

         3.       DURATION OF AGREEMENT. This Agreement shall become effective
on the date first set forth above and shall remain in effect for a period of
three years. Thereafter, this Agreement may annually be extended or modified by
mutual agreement between the Parties for additional twelve month periods.

         4.       PLACE OF WORK. The Consultant shall perform his obligations
and responsibilities hereunder at the Company's headquarters or such other place
as is reasonably requested by the Company.

         5.       COMPENSATION

                  a.       Dr. Santilli shall be compensated at the rate of
$10,000 (ten-thousand dollars) per month, payable in equal amounts of $5,000
payable on the 15th and 30th of each month for the duration of this Agreement.
All payments shall be made in the name of the Institute for Basic Research.

                  b.       STOCK OPTIONS. As a part of his compensation, at the
end of each research and development program as that program is defined by the
Company's Board of Directors Dr. Santilli shall receive Options to acquire
100,000 of the Company's Common Shares at the fair market price on the date of
issuance. However, pursuant to this item 5b, Dr. Santilli may not receive more
than 100,000 such options during any annual period of this Agreement. For the
purposes of this Agreement, the "fair market price" shall be that amount equal
to an average of the closing "bid" price of the Company's publicly traded
securities for a five day period preceding the date of issuance.

                  c.       STOCK INCENTIVES. During any annual period of this
Agreement when the Minimal Sales set forth in item 7 of the Technology Exclusive
License and Royalty Agreement reflect, at a minimum, the following amounts, then
the Stock Options granted in item 5b above shall be doubled:

                  First Year                $1,000,000
                  Second Year               $3,000,000
                  Subsequent Years          $6,000,000

         6.       BENEFITS

                  a.       Dr. Santilli shall at all times remain an independent
contractor and not an employee of the Company. As such, Dr. Santilli is not
entitled to participate in

                                       2
<PAGE>

the Company's insurance program nor other programs which may from time to time
be adopted by the Company for employees.

                  b.       Dr. Santilli shall receive three weeks per annual
period of paid vacation for the duration of this Agreement.

         7.       TERMINATION

                  a.       This Agreement may be terminated by the Company
immediately provided:

                           (i)      Consultant is unable or unwilling to provide
the consultant services by reason of temporary or permanent illness, disability
incapacity or death.

                           (ii)     If there shall be any breach or default of
any obligation of the Consultant pursuant to the section 8 marked Nondisclosure,
Non-Compete, Non-Circumvention of this Agreement.

                           (iii)    If there will be any breach or default of
this Agreement and such breach or default is not cured within a thirty day
period following notice of such breach or default.

                           (iv)     At the will of the Company at the end of the
first three year term.

                  b.       The Consultant may terminate this Agreement
immediately provided:

                           (i)      There is a breach or default of any material
obligation of the Company which breach or default is not cured within thirty
(30) days of written notice of such breach or default.

                           (ii)     If the Company files for protection under
the federal bankruptcy laws or any bankruptcy petition or petition for receiver
is commenced by a third party against the Company, any of the foregoing of which
remains undismissed for a period of sixty (60) days.

                  c.       This Agreement may be cancelled by either Party, with
or without cause upon thirty (30) days written notice to the other Party, sent
by telex or facsimiles, registered mail or delivered personally.

                  d.       If this Agreement is terminated without cause by the
Company, Dr. Santilli shall be paid a lump sum severance payment in lieu of any
other compensation or benefits otherwise payable in an amount equal to the
number of months remaining under this Agreement or any subsequent amendment
multiplied by $3,000.

                                       3
<PAGE>

                  e.       If this Agreement is terminated for cause, then there
shall be no further obligation on the part of the Company to make any payment
whatsoever to Dr. Santilli regardless of the remaining unfulfilled portions of
this Agreement or any subsequent amendment hereto.

                  f.       Should Dr. Santilli terminate this Agreement without
cause, Dr. Santilli shall forfeit all compensation which would otherwise be due
hereunder.

         8.       NON-CIRCUMVENTION

                  a.       The Consultant will not, at any time, in any fashion,
form or manner, either directly or indirectly, divulge, disclose or communicate
to any person, firm or corporation in any manner whatsoever any information of
any kind, nature, or description concerning, any matters affecting or relating
to the business of the Company, including, without limitation, the names of any
its customers, the prices it obtains or has obtained, or at which it sells or
has sold its products, or any other information concerning the business of the
Company, its manner of operation, or its plans, processes or other data of any
kind, nature or description without regard to whether any or all of the
foregoing matters would be deemed confidential, material, or important. The
parties hereby stipulate that, as between them, the foregoing matters are
important, material and confidential, and gravely affect the effective and
successful conduct of the business of the Company and its good will, and that
any breach of the terms of this section is a material breach of this Agreement.

                  b.       During the term of this Agreement and thereafter for
a period of one (1) year, the Consultant shall not, without prior written
consent of the Company, disclose to anyone any Confidential Information.
"Confidential Information" for the purposes of this Agreement shall include the
Company's proprietary and confidential information such as, but not limited to,
customer lists, business plans, marketing plans, financial information, designs,
drawings, specification, models, software, or any data related to any
noncommercialized or prototype product, service, technique or purpose thereof.
The parties hereby stipulate that, as between them, the foregoing matters are
important, material and confidential, and gravely affect the effective and
successful conduct of the business of the Company and its good will, and that
any breach of the terms of this section is a material breach of this Agreement.
Confidential Information shall not include any information that:

                           (i)      is disclosed by the Company without
restriction;

                           (ii)     becomes publicly available through no act of
the Consultant;

                           (iii)    is rightfully received by Consultant from a
third party.

                  c.       During the term of this Agreement and for a period of
one (1) year thereafter, the Consultant shall not solicit business with any
clients or prospective clients which become acquainted with the Consultant for
any reason during the term of

                                       4
<PAGE>

this Agreement or any subsequent amendment hereto. Further, during the term of
this Agreement and for a period of one (1) year thereafter, the Consultant shall
not compete directly or indirectly, either for his own account, or as a partner,
shareholder, officer, director, employee, agent or otherwise, own, manage,
operate, control be employed by, participate in, consult with, perform service
for, whether for compensation or not, any entity or individual in a business
similar to that of the Company. In the event any of the provisions of this
section are determined to be invalid by reason of their scope or duration, this
section shall be deemed modified. to the extent required to cure the invalidity.
In the event of a breach, or a threatened breach of this section the Company
shall be entitled to obtain an injunction restraining the commitments or
continuance of the breach, as well as any other legal or equable remedies
permitted by law.

         9.       INDEPENDENT CONTRACTOR. Consultant is and throughout this
Agreement shall be an independent contractor and not an employee, partner or
agent of the Company. Unless specifically specified herein, the Consultant shall
not be entitled to nor receive any benefit normally provided to the Company's
employees such as, but not limited to, vacation payment, retirement, health care
or sick pay. The Company shall not be responsible for withholding income or
other taxes from the payments to Consultant. Consultant shall be solely
responsible for filing all returns and paying any income, social security or
other tax levied upon or determined with respect to the payments made to
Consultant pursuant to this Agreement.

         10.      WAIVERS. No waiver of any default shall be implied from any
delay or omission by the parties to take action on account of such default, and
no express waiver shall affect any default other than the default specified in
the waiver and it shall be operative only for the time and to the extent therein
stated.

         11.      BENEFIT. This Agreement is made and entered into for the sole
protection and benefit of the Parties hereon, their successors and assigns and
no other person or persons have any right to action hereon or rights as a third
party beneficiary as a result of the execution of this Agreement.

         12.      ASSIGNMENT. The rights and obligations of either Party hereto
are non-assignable.

         13.      TERMS. Whenever the context and construction so require, all
words used in the singular number herein shall be deemed to have been used in
the plural, and vice versa, and the masculine gender shall include the feminine
and neuter and the neuter shall include the masculine and feminine. This
Agreement is the product of intensive negotiations between the parties, and as
such, the identity of the drafter shall not be relevant in construction of this
Agreement.

         14.      GOVERNING LAW AND JURISDICTION. This Agreement and all matters
relating thereto shall be governed by and construed and interpreted in
accordance with the laws of the State of Florida. The Parties hereby submit to
the jurisdiction of the state and federal courts located in Pinellas County,
Florida.

                                       5
<PAGE>

         15.      SAVINGS CLAUSE. Invalidation of any one or more of the
provisions of this Agreement shall in no way affect any of the other provisions
hereof, which shall remain in full force and effect.

         16.      EXECUTION IN COUNTERPARTS. This Agreement may be executed in
two or more counterparts, each of which shall be deemed to be an original, but
all of which shall constitute one and the same instrument, and in making proof
of this Agreement, it shall not be necessary to produce or account for more than
one such counterpart.

         17.      CAPTIONS. The captions herein are inserted only as a matter of
convenience and for reference and in no way define, limit or describe the scope
of this Agreement nor the intent of any provision hereof.

         18.      ENTIRE UNDERSTANDING. This Agreement constitutes the entire
understanding between the Parties and all prior or contemporaneous oral or
written agreements, understandings, representations and statements are merged
into this Agreement.

         19.      NOTICES. Any and all notices, designations, consents, offers,
acceptances or any other communication provided for herein shall be given in
writing by certified mail or by reputable overnight courier service which shall
be addressed as follows:

         If to USMAGNEGAS, Inc.

         Mr. Leon Toups
         President and Chief Executive Officer
         USMAGNEGAS, Inc.
         35246 US Highway 19 North,
         Suite 115,
         Palm Harbor, Florida 34684

         If to Dr. Santilli

         Dr. Ruggero Santilli
         90 Eastwind Court,
         Palm Harbor, Florida 34683

         20.      SURVIVAL. The representations and warranties and provisions of
this Agreement shall survive any closing hereunder.

         21.      ATTORNEYS' FEES. In the event that any party is required to
engage the services of legal counsel to enforce its rights under this Agreement,
the prevailing party shall be entitled to reasonable attorneys' fees and costs
from the other party,

                                       6
<PAGE>

which in the event of litigation may include fees and costs incurred at trial,
on appeal and incident to any bankruptcy proceeding.

         22.      WAIVER OF JURY TRIAL. BY ACCEPTANCE HEREOF, THE PARTIES AGREE
THAT NONE OF THEM SHALL SEEK A JURY TRIAL IN ANY LAWSUIT, PROCEEDINGS,
COUNTERCLAIM, OR ANY OTHER LITIGATION PROCEDURE BASED UPON OR ARISING OUT OF
THIS AGREEMENT OR ANY INSTRUMENT EVIDENCING OR RELATING TO THIS AGREEMENT. NONE
OF THE PARTIES WILL SEEK TO CONSOLIDATE ANY SUCH ACTION, IN WHICH A JURY TRIAL
HAS BEEN WAIVER, WITH ANY OTHER ACTION IN WHICH A JURY TRIAL HAS NOT BEEN
WAIVED. THE PROVISIONS OF THIS PARAGRAPH HAVE BEEN, FULLY NEGOTIATED BY THE
PARTIES, AND THIS PROVISION SHALL BE SUBJECT TO NO EXCEPTIONS.

         23.      Immediately upon execution of this Agreement, section 7g of
that Technology Exclusive License and Royalty Agreement shall be null and void
and no longer binding on the parties thereunto pertaining.

         IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as
of the date first given above.

For Dr. Ruggero Santilli                         For USMAGNEGAS, Inc.

/s/ DR. RUGGERO MARIA SANTILLI                   /s/ LEON TOUPS
------------------------------                   ---------------------
Dr. Ruggero Maria Santilli                       Leon Toups, President

For the Institute for Basic Research

/s/ RUGGERO SANTILLI
---------------------------
Ruggero Santilli, President

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00024-of-00352.parquet"}]]